Lizinopril-Pharmlend

General characteristics. Structure:

Active ingredient: 10 mg of lisinopril.

Excipients: cellulose microcrystallic, starch corn, povidone, Natrium benzoicum, talc, magnesium stearate, sodium glikolit starch, colloid silicon dioxide.

Cardiological anti-hypertensive drug.

Pharmacological properties:

Pharmacodynamics. APF inhibitor, prevents angiotensin-Iv transition angiotenzin-P and reduces its vasoconstrictive action, and also its stimulating influence on products of Aldosteronum in adrenal glands. Reduces the general peripheric vascular resistance, system the ABP, pressure in pulmonary capillaries, causes increase in cordial emission and increase in tolerance of a myocardium to cordial loadings in patients with heart failure. For the second time increases activity of a renin of a blood plasma.

Pharmacokinetics. Lisinopril is easily adsorbed in digestive tract. Half-life about 7 hours. Excretion with urine.

After oral reception of lisinopril the peak of concentration of drug in blood serum is reached within 7 hours. Decrease in serumal concentration prolongs a terminal phase which does not promote drug cumulation. This terminal phase perhaps reflects a delay of saturation of APF and is not proportional to a drug dose. Lisinopril does not contact other serumal proteins.

Lisinopril is not metabolized completely and removed in an invariable view with urine.

Meal does not influence bioavailability of drug. About 25% of the accepted dose become bioavailable with high variability (6-60%) depending on a dose (5 - 80 mg). Bioavailability of lisinopril decreases to 16% at patients with heart failure P - Ivklassov on NYHAI the volume of distribution a little lower than at healthy people. Increase in a dose of lisinopril is followed by increase in effective concentration and increase in duration of action. Disturbance of renal function leads to decrease in elimination of drug. Clinically significant decrease in glomerular filtering less than 30 ml/min. If glomerular filtering above this indicator half-life changes slightly. Leads considerable renal failures to increase in level of lisinopril in blood serum, to increase in peak concentration and longer action. Elderly patients have higher levels of drug in blood, than young people. Lisinopril can be removed from plasma by a hemodialysis.

Indications to use:

Hypertension, symptomatic arterial hypertension, heart failure.

For treatment of a hypertension can it is applied as monotherapy or in combination with classical anti-hypertensive drugs.

As auxiliary therapy for treatment of heart failure at the patients receiving cardiac glycosides and diuretics.

Route of administration and doses:

At heart failure from 2,5 to 20 mg a day.

At a hypertension from 10 to 40 mg a day.

To patients with the disturbance of water and electrolytic exchange, a renal failure, renovascular hypertensia and also receiving diuretics, the dose is selected individually.

Features of use:

Disturbance of renal function: as a result of inhibition renin-angiotensin-aldosteronovoy of system, change of renal function can be expected at patients with individual sensitivity.

At patients with a severe form of heart failure at whom renal function can depend on activity system renin-angiotensin-aldosteronovoy treatment by APF-inhibitors, including lisinopril can lead to an oliguria and/or a progressive azotemia and is rare to an acute renal failure and/or death.

Patients with hypertensia with a unilateral or bilateral renal artery stenosis, can have an increase in nitrogen in urea of blood and serumal creatinine. Experience with other APF inhibitors assumes that these increases are usually reversible after the treatment termination by lisinopril and/or diuretic. At such patients renal function has to be controlled during the first several weeks of treatment.

Side effects:

Weakness, headache, diarrhea, cough, nausea, orthostatic collapse, adynamy, rash, heartbeat, impotence.

Change of laboratory indicators: increase in levels of urea, creatinine, bilirubin - indicators return to normal after drug withdrawal. Decrease in uniform elements of blood, hemoglobin, hematocrit. The hyperpotassemia can be observed.

Symptomatic hypotension: can develop at patients with heavy heart failure, the patients accepting other anti-hypertensive drugs at patients with dehydration.

It can be observed allergic reactions and ангиоотек persons, extremities, lips, the person, a throat, a trachea.

Treat the most significant and serious side effects: depression of function of kidneys, ikterichnost of skin and scleras, thorax pains, abdominal pain, asthma, pharyngalgias, hoarseness of a voice, feeling of heat or fever.

Non-constant cough, xeroderma and mucous membranes can be observed.

The headache, nausea, muscular weakness, numbness of feet, brushes, hands, lips, skin rash is sometimes noted.

 In case of existence of side effects of their expressiveness it is necessary to see a doctor immediately.

Interaction with other medicines:

Together with thiazide diuretics lisinopril more expression reduces arterial pressure.

At simultaneous use of lisinopril, diuretic drugs and drugs of a digitalis there is a decrease in resistance of vessels of a small circle of blood circulation and pulmonary pressure, and also reduction of load of a cardiac muscle.

Lisinopril together with diuretic drugs and cardiac glycosides stops a number of symptoms characteristic of congestive heart failure (hypostases, a venous distsirkulyation, an asthma).

Strengthens risk of development of a hyperpotassemia against the background of reception of kaliysberegayushchy diuretics and drugs of potassium.

Antacids and холестирамин reduce absorption from a GIT.

Contraindications:

Hypersensitivity, pregnancy, aorta stenosis, renal failure, pulmonary heart, children's age.

Lisinopril is contraindicated to patients with already known sensitivity to this drug and at patients with angiootyoky in the anamnesis, APF connected with treatment in the past.

Storage conditions:

To store in the place protected from moisture and light at a temperature not over +25 ºС. To store in the place, unavailable to children. Period of validity 3 years. 

Issue conditions:

According to the recipe

Packaging:

On 20 or 30 tablets in bank of polymeric. On 10 tablets in a blister strip packaging. 1 bank or 3 blister strip packagings together with a leaf insert in secondary packaging.